Prelude Therapeutics Incorporated (PRLD) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Prelude Therapeutics Incorporated (NASDAQ: PRLD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.88 (-5.37% 1D, market cap $309.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRLD ranks #680 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRLD carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ENTA (Enanta Pharmaceuticals Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $311.9M) and ARCT (Arcturus Therapeutics Holdings Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $313.5M). Among the 5-stock peer group, PRLD leads on earnings multiple (N/A) while PRLD leads on capital efficiency (-35.0% ROIC).
Per PRLD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001678660), Prelude Therapeutics Incorporated generated $12.1M in revenue (+73.4% YoY), -$99.5M in net income, and -$56.4M in free cash flow against $141.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While PRLD currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.35) and Max Pain ($4.07) forces dealer call-delta covering toward $7.17.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Prelude Therapeutics Incorporated (PRLD) dropped -5.37% to $3.88, trading at 48% of its 52-week range ($1.17 – $6.83). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
WILMINGTON, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Charda
Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could le
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +73.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PRLD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PRLD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Prelude Therapeutics Incorporated (PRLD) ranks #680 by composite RQD confidence (33/100, grade E) and #512 by equity capitalization ($309.6M). Within this direct 5-issuer industry benchmark cohort, PRLD leads on earnings valuation at N/A trailing P/E, while PRLD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PRLD currently leads its immediate peer cohort in composite quantitative strength at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PRLD
ACTIVE
Prelude Therapeutics Incorporated | E | 33/100 | — | — | -35.0% | -5.37% | $309.6M | Benchmark Subject |
| ENTA Enanta Pharmaceuticals Inc. | E | 20/100 | — | — | -35.0% | -3.95% | $311.9M | /enta-vs-prld → |
| ARCT Arcturus Therapeutics Holdings Inc. | E | 25/100 | — | — | -35.0% | -9.22% | $313.5M | /arct-vs-prld → |
| IRD Opus Genetics Inc. | E | 23/100 | — | — | -35.0% | +0.55% | $305.3M | /ird-vs-prld → |
| BNTC Benitec Biopharma Inc. | E | 30/100 | — | — | -35.0% | -1.02% | $304.9M | /bntc-vs-prld → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Prelude Therapeutics Incorporated (PRLD) reported GAAP revenue of $12.1M (+73.4% vs. FY2024 revenue of $7.0M ) , GAAP net income of -$99.5M, operating cash flow of -$56.3M, and free cash flow of -$56.4M (+45.6% YoY). On the balance sheet, PRLD closed FY2025 with $141.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $12.1M | -$99.5M | -$56.3M | -$56.4M | $141.3M | — |
| FY2024 (FY) | 2024-12-31 | $7.0M | -$127.2M | -$102.9M | -$103.7M | $175.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$121.8M | -$107.1M | -$107.1M | — | — |
As of 2026-11-03, Prelude Therapeutics Incorporated (NASDAQ: PRLD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.88 (-5.37% 1D, market cap $309.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRLD ranks #680 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRLD carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ENTA (Enanta Pharmaceuticals Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $311.9M) and ARCT (Arcturus Therapeutics Holdings Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $313.5M). Among the 5-stock peer group, PRLD leads on earnings multiple (N/A) while PRLD leads on capital efficiency (-35.0% ROIC).
Per PRLD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001678660), Prelude Therapeutics Incorporated generated $12.1M in revenue (+73.4% YoY), -$99.5M in net income, and -$56.4M in free cash flow against $141.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PRLD last traded at $3.88 (-5.37% on volume of 218,111 shares), positioning the stock -10.80% below its 50-day simple moving average ($4.35) and -3.72% below its 200-day simple moving average ($4.03). Across its 52-week range of $1.17 to $6.83, PRLD sits at the 47.9% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.40 to $4.36).
Why PRLD Stock dropped -5.37% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, PRLD scores 41 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: the Fundamental Cash Engine scores 8/20 (ROIC of -35%; FCF yield of -17.23%), indicating the business is not currently generating cash returns on capital. Whale 13F Flow scores 10/20, reflecting institutional accumulation and options positioning that is present but not strong enough to lift the rating. Insider Conviction scores 3/20 on the basis of SEC Form 4 and Congressional PTR cluster flow, the weakest pillar in the rating. Macro Regime Fit scores 9/20 with a beta of 1.0 and sector sensitivity noted. Forensic Balance Sheet scores 11/20, drawing on an Altman Z of 2.5, a Piotroski F of 4/9, and a Debt/Equity of 0.5.
For a prospective investor, the upside case rests on the business reaching a point where operating losses narrow; the source data does not show that yet. Valuation cannot be anchored to earnings because P/E and EPS are not available in source data, so any assessment must lean on balance sheet resilience and cash burn trajectory. The rating signals that the balance sheet and cash flow profile are the primary risk factors. This is an educational summary of the rating's components, not personalized advice.
Prelude Therapeutics Incorporated (PRLD) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, its market capitalization is $0.3B. The source data does not describe the specific products sold, the customer base, or the detailed revenue model. Reported revenue of $12.1M for FY 2025 is shown in the SEC financials, but its composition is not detailed in source data.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $12.1M | $-104.6M | $-99.5M | N/A | $-56.4M | $35.3M | N/A |
| FY 2024 | $7.0M | $-139.7M | $-127.2M | N/A | $-103.7M | $12.5M | N/A |
| FY 2023 | $0.0M | $-132.3M | $-121.8M | N/A | $-107.1M | N/A | N/A |
Per the SEC financials, the company reported operating losses across all three periods, with FY 2025 operating income of $-104.6M narrowing from $-139.7M in FY 2024. Operating margin is -60% and net margin is -60% per market data, with gross margin at 0%. ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 4/9, and Debt/Equity is 0.5. Cash rose to $35.3M in FY 2025 from $12.5M in FY 2024, but free cash flow remained negative at $-56.4M.
Per the recent news feed, several headlines reference a potential $100M Incyte option tied to the JAK2 and KAT6A programs, and a Lilly deal with a Citizens price target of USD 6.00. A TradingView item cites a Q3'26 revenue estimate of 29.00M USD. Several items are flagged YELLOW (market wire) and one GREEN (catalyst, related to a healthcare sector earnings preview). These headlines are referenced by title only; the source data does not confirm deal terms beyond these headlines. Risk watch items include the sustained operating losses and negative free cash flow noted above. Per the Butterfly Supply-Chain Graph, no proprietary signals or supply-chain links are recorded.
Real-time company headlines, analyst actions, and sector developments for Prelude Therapeutics Incorporated (PRLD) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Prelude Therapeutics Incorporated (PRLD) market action, institutional positioning, and fundamental catalysts.
Welcome to the PRLD (Prelude Therapeutics Incorporated) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on PRLD, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Prelude Therapeutics Incorporated expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on PRLD, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $4.10 (52-wk range $1.17 - $6.83), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).